TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. The company was incorporated in 1993 and is based in Morrisville, North Carolina.

Period	PE Ratio
2016-12-31	-34.12
2017-12-31	-28.58
2018-12-31	-23.73
2019-12-31	-27.85
2020-12-31	-22.56
2021-12-31	-20.76
2022-12-31	-37.39
2023-12-31	606.56
2024-12-31	341.19
2025-12-31	17.61

	A	B	C	D
1	Symbol	Price	Change	Volume
2	TGTX	$54.59	+2.57%	1.35M
3
4
5

TG Therapeutics Inc. (TGTX) PE Ratio

PE Ratio Data

Get TG Therapeutics Inc. Data in Excel

More TGTX Financial Data